1-> Shares of BioCryst Pharmaceuticals (BCRX+3.3%) are higher this morning following purchases by two company insiders. CFO Anthony Doyle acquired35,258 shares at $12.48 per share for a total of ~$402,580. Vincent Milano, a member of the board of directors,bought 7.5K sharesat $12.19 per share for a total of $91,425. Earlier this week, Royalty Pharma (RPRX-0.0%)purchased additional royalty interests in BioCryst. Van I'm leaning towards VIR & BCRX
Stoney!!!! Anything you post today will be well received by me. You're my safe space! Cooter & the Inbreds (great name for a country band now that I wrote that) rolled out a few hours ago. Thank god. And you wonder why I hate holidays. I'm going for a cheap solo cruise on the SS Omicron for Xmas if those mf'rs get any idea about "more shopping". It's like "listen up idiot... they have effing WMT's everywhere. You're not gonna miss out on a 70" TV for $399 by not coming around here." Poor Muttley.... she's just keeps giving me this sad "wtf?" look. "Are they coming back?" In dog years... she's way too old for these sometimes semi-annual disruptions to her peace. "AND DON'T FEED HER TABLE SCRAPS YOU IDIOT!!!!" Yeah. That went over well. Now I'm a "yuppy". ....whatever.
Stoney!!!!! Are my eyes deceiving me or did the Giants win a game?! ++++++++++++++++++++++++++++++++++++++++++++++ I didn't get around to Krispy Kreme. The chart looks ok. I think it heads up near term. It's only been trading 104 days. Did it go private and then come back out? I swear it used to be a story stock back in the day. Maybe I'm mistaken. I'd read the S-1 before you put any money it for the ira or the college fund. Check the lock-up. +++++++++++++++++++++++++++++++++++++++++++++++ Blast from the past: "He did it again". It did make it to the $70's by July. I lost interest and didn't follow it. It had a little bounce and flirted with the $80's for a few months, and now it has tanked down to the mid $60's. Guess what Stoney?!!!! We're making ESTA our Cyber-Monday Gummy Pick. $ESTA-------> $66.41 $64.80 would be a great entry if it drops today. $70 is on the way though. EDIT: All that and this too. Good sign.
Are my eyes deceiving me or did the Giants win a game?! All Birds is a cult. My brother was sporting a pair at Thanksgiving and made me try on his pair. I couldn't get my fat/wide foot in and my high arches did not like the flatness of the shoe... This drew huge response everyone is wearing them apparently.. it is a cult<--- IDEA #1--> BIRD Guggenheim starts Allbirds at Buy, sees 50% potential upside 08:57 BIRD Guggenheim analyst Robert Drbul initiated coverage of Allbirds with a Buy rating and $30 price target, which implies 50% potential upside from current levels. Allbirds, which has developed a "highly differentiated, comfortable, and competitive" footwear and apparel product offering using naturally derived materials, is poised to grow revenues by 25% to 30% over the next three to five years, projects Drbul. He foresees continued market share gains for sustainable fashion as well as gains from overall footwear and apparel and views Allbirds being "in a very strong position to lead the way" in that context, stating that he believes revenues should approach $750M in 2025.
BioCryst begins patient enrollment in REDEEM-2 trial of BCX9930 08:50 BCRX What is BCX9930? Good question back to you on that before we buy it!
IDEA #2 REKR Rekor One to be deployed in Stamford, Watertown and Middlebury, Connecticut 07:41 REKR Rekor Systems announced that its Rekor One platform will be deployed in Stamford, Watertown and Middlebury, Connecticut. In the past six months, the Company's technology has expanded into 26 cities in the United States. Additional new cities include Chattanooga, Tennessee; Tampa, Florida; Columbus, Ohio; Salt Lake City; Las Vegas; and St. Louis. This significant growth highlights the Company's growing business among new and current customers as part of the Company's land-and-expand strategy.
Oh Boy... ruh row. This is what we have been waiting for-- Gritstone says Omnicron variant has minimal impact on TCEs in COVID-19 vaccines 07:19 GRTS
Ok... this shows smart management for one thing although a lot of people are chirping but GRTS goes after one other area besides the Spikea protein so it ios exactly what we are trying to do here-- The stock is hardly moving-- EMERYVILLE, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the SARS-CoV-2 T cell epitopes (TCEs) administered within its self-amplifying mRNA (SAM) COVID-19 vaccines are minimally impacted by mutations found within the Omicron (B.1.1.529) variant, reinforcing the platform’s potential to address emerging variants of concern.
Sequence analysis suggests that Gritstone’s TCEs are minimally impacted by Omicron. Specifically, of the 146 non-Spike TCE delivered within Gritstone's vaccine currently in clinical trials in the UK and US, only 3 (~2%) are impacted by Omicron. Similar minimal impact of Omicron is observed in two new vaccine TCE constructs expected to enter clinical trials in South Africa before year end. “Our value proposition in immunotherapy has always centered around two core pillars – cutting-edge TCE identification and delivering potent vaccines that can elicit strong, broad, and durable immune responses,” said Andrew Allen, MD, PhD, Gritstone’s Chief Executive Officer. “Strong neutralizing antibody responses to Spike-based vaccines have been shown to be highly protective against COVID-19. However, the possibility of substantial viral resistance arising from Spike mutations has always been present, and Omicron may represent the embodiment of this threat. While engineering an Omicron form of Spike is achievable, it is clearly ideal to both address novel Spike variants and also reduce the likelihood of further variants arising, by delivering a coordinated immune attack against both Spike and other more conserved SARS-CoV-2 genes. This is the path Gritstone has followed to date.
1- GRTS (GRTS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD 11.12+0.28 (+2.58%) At close: November 26 1:00PM EST 11.35+0.23 (+2.07%)<----------- Pre-Market:09:21AM EST GRTS only up 2% 2-VIR Vir Biotechnology, Inc. (VIR) NasdaqGS - NasdaqGS Real Time Price. Currency in USD 36.00+3.98 (+12.43%) At close: November 26 1:00PM EST 38.75+2.75 (+7.64%)<----------------- Pre-Market:09:21AM EST VIR up 7.6%